Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial-Reference-Cited by-同舟云学术

Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial

Published:2007-11 Issue:6 Volume:28 Page:763-769
ISSN:1551-7144
Container-title:Contemporary Clinical Trials
language:en
Short-container-title:Contemporary Clinical Trials

Author:

Fleshner Neil,Gomella Leonard G.,Cookson Michael S.,Finelli Antonio,Evans Andrew,Taneja Samir S.,Scott Lucia M.,Wolford Eric,Somerville Matthew C.,Rittmaster Roger

Publisher

Elsevier BV

Subject

Pharmacology (medical),General Medicine

Reference22 articles.

1. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CaPSURE), a national disease registry;Cooperberg;J Urol,2004

2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/downloads/STT/CAFF2006pwsecured.pdf. Accessed September 14, 2007.

3. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis;Brenner;J Clin Oncol,2005

4. Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer;Klotz;J Urol,2004

5. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer;Klotz;Eur Urol,2005

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tissue Preservation: Active Surveillance and Focal Therapy as Complimentary Strategies;Active Surveillance for Localized Prostate Cancer;2017-09-30

2. The role of ions, heavy metals, fluoride, and agrochemicals: critical evaluation of potential aetiological factors of chronic kidney disease of multifactorial origin (CKDmfo/CKDu) and recommendations for its eradication;Environmental Geochemistry and Health;2015-10-13

3. Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial1Share senior authorship.;Urologic Oncology: Seminars and Original Investigations;2015-03

4. Current Situation in the Use of 5-Alpha Reductase Inhibitors for Prostatic Diseases;Üroonkoloji Bülteni;2014-12-05

5. 5-Alpha-reductase inhibitors in diseases of the prostate;Current Opinion in Endocrinology, Diabetes & Obesity;2014-12